Physician profile
David A Barr
NPI 1437239969
$1,220.42
in general payments reported to CMS, 2019-2025
27 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $15.50 · 2022: $153 · 2023: $187 · 2024: $397 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $213.41 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $138.67 | 2019-2025 | Veozah |
| Abbvie INC. | $112.18 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $101.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $78.45 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.67 | 2019-2024 | Jardiance |
| Pfizer INC. | $65.57 | 2019 | |
| Medtronic, INC. | $44.87 | 2022-2024 | Intellis Adaptivestim |
| Jazz Pharmaceuticals INC. | $41.27 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.09 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $37.38 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $28.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $26.97 | 2019-2022 | |
| Amgen INC. | $25.42 | 2022 | |
| Abbott Laboratories | $19.14 | 2024 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.56 | 2023 | Onpattro |
| Axsome Therapeutics, INC. | $16.67 | 2024 | Auvelity |
| Exact Sciences Corporation | $14.93 | 2024 | Cologuard Collection Kit |
| Biogen, INC. | $14.61 | 2025 | Zurzuvae |
| Boston Scientific Corporation | $13.53 | 2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $13.33 | 2024 | |
| Merck Sharp & Dohme LLC | $13.14 | 2019 | |
| Echosens North America, INC. | $13.04 | 2025 | Fibroscan |
| Astrazeneca Pharmaceuticals LP | $12.81 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.39 | 2022 | |
| Allergan, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.